Turning Point Therapeutics shares more than doubled on Friday | Invezz
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Jun 3, 2022
The $76 a share deal is expected to close in the third quarter of 2022.
Turning Point Therapeutics shares jumped more than 100% on Friday.
Bristol-Myers to pay $76 a share for TPTX
The pharmaceutical giant is paying $76 a share for Turning Point that represents a 116% premium on the price at which TPTX closed the regular session on Thursday.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
According to Bristol-Myers, it will use cash on hand to finance the acquisition that it forecasts will take until 2025 to be accretive to its non-GAAP per-share earnings. BMY is roughly flat on Friday.
The news comes weeks after Turning Point Therapeutics Inc reported wider-than-expected per-share loss for its fiscal first quarter.
Deal to close in the third quarter of 2022
Both Bristol-Myers and Turning Point have already secured approval from their respective boards. The transaction is expected to complete in the third quarter of 2022, subject to customary closing conditions.
TPTX Board of Directors have recommended that shareholders accept the tender offer. In the press release this morning, Turning Point Therapeutics Inc CEO Athena Countouriotis said:
With Bristol Myers’ leadership in oncology, strong commercial capabilities and manufacturing footprint, we’ll be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer.
75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Health & pharmaceuticals
Stocks & Shares